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Breast cancerAlthough bone morphogenetic protein-6 (BMP-6) has been identiﬁed as a tumor suppressor associated with
breast cancer differentiation and metastasis, the potential roles of BMP-6 in regulating cell cycle progression
have not been fully examined. In the present study, we provide the novel ﬁnding that induction of BMP-6 in
MDA-MB-231 breast cancer cells signiﬁcantly inhibits cell proliferation by decreasing the number of cells in S
phase of the cell cycle, resulting in inhibition of tumorigenesis in a nude mouse xenograft model. Further inves-
tigation indicated that BMP-6 up-regulates the expression ofmicroRNA-192 (miR-192) inMDA-MB-231 cells. El-
evated expression of miR-192 caused cell growth arrest, which is similar to the effect of BMP-6 induction.
Importantly, depletion of endogenous miR-192 by miRNA inhibition signiﬁcantly attenuated BMP-6-mediated
repression of cell cycle progression. In breast cancer tissue, miR-192 expression is signiﬁcantly down-
regulated in tumor samples and positively correlateswith the expression of BMP-6, demonstrating the inhibitory
effect of BMP-6 on cell proliferation through miR-192 regulation. Additionally, using the RT2 Proﬁler PCR Array,
retinoblastoma 1 (RB1) was identiﬁed as a direct target of the BMP-6/miR-192 pathway in regulating cell prolif-
eration in breast cancer. In conclusion, we have identiﬁed an important role for BMP-6/miR-192 signaling in the
regulation of cell cycle progression in breast cancer. Furthermore, BMP-6/miR-192was expressed at low levels in
breast cancer specimens, indicating that this pathwaymight represent a promising therapeutic target for breast
cancer treatment.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cell division is a physiological process that occurs under many cir-
cumstances in almost all tissues. Under normal conditions, the balance
between proliferation and programmed cell death is tightly regulated
to ensure tissue and organ integrity. Changes in the activity of growth
factors affect these orderly processes by disrupting the program that
regulates cell cycle entry and death, resulting in the conversion of
normal cells into tumor cells [1,2]. One of the most well-characterized
growth factors in breast cancer is bone morphogenetic protein-6
(BMP-6), which belongs to the transforming growth factor-β (TGF-β)
superfamily [3–5]. BMP-6 has been identiﬁed as a multifunctional
molecule with distinct roles in embryogenesis and organogenesis
[6–8]. In addition to the pivotal role of BMP-6 in endochondral bone for-
mation [9–12], several recent studies have shown that BMP-6 is closely
associated with breast cancer differentiation and metastasis [5,13–18].
BMP-6 reverses the epithelial–mesenchymal transition (EMT) in breast
cancer by restoring E-cadherin expression [14,17]. Expression of BMP-6
has also been reported to inversely correlate with the metastaticai University, 94 Weijin Road,
22 23505501.
ights reserved.potential of both breast cancer cell lines and clinical tumor specimens
[14,16]. Molecular analysis has identiﬁed metastasis-related factors,
such as δ-crystallin enhancer-binding factor 1 (δEF1) and matrix
metalloproteinase-9 (MMP-9), that are involved in BMP-6-mediated
inhibition of breast cancer growth and metastasis [16–18]. In addition,
Takahashi et al. have reported that BMP-6 signiﬁcantly represses
estrogen-induced mitosis in MCF-7 breast cancer cells via impaired
expression of steroid sulfatase [19]. However, information regarding a
direct effect of BMP-6 on breast cancer proliferation does not currently
exist, and the elucidation of such a mechanism would provide novel
approaches for therapy.
MicroRNAs (miRs) are short noncoding RNAs of approximately 22
nucleotides in length that play regulatory roles in mammalian gene
expression [20–23]. miRs induce posttranscriptional gene repression by
blocking protein translation (through binding to the 3′-UTR of target
genes) or by inducing mRNA degradation. miRs exert their regulatory
functions under both physiological and pathological conditions. Recent
evidence has suggested multiple functions for miRs, including suppress-
ing tumor initiation and development, promoting or inhibiting metasta-
sis, and increasing sensitivity or resistance to chemotherapy and targeted
agents in breast cancer. Several oncogenicmiRs, such asmiR-21 [24–26],
miR-155 [27], and miR-27a [28], have been found to repress the expres-
sion of tumor suppressor genes and/or genes responsible for tumor
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Fig. 2. BMP-6 inhibits tumorigenesis in vivo in BALB/c nudemice. A. A total of 1 × 106 ΔBMP-6 andΔControl cells were injected into themammary fat pads of nudemice (n = 7). Tumor
developmentwas followed for 3 weeks, and then themicewere sacriﬁced. Cross-sectional tumor diametersweremeasured externally, and the approximate tumorweights (B) and tumor
volumes (C) were calculated as described in the “Materials and methods” section. * indicates p b 0.05 in an unpaired Student's t-test compared with the ΔControl. D. The expression of
BMP-6 in breast cancer xenografts was examined by Western blotting. Actin was used to normalize the BMP-6 levels. E. PCNA expression in breast cancer xenografts was examined by
immunohistochemical staining and Western blotting. Scale bars, 50 μm.
2381F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–2390growth and metastasis. However, miRs may also act as tumor suppres-
sors. For example, miR-125a/b [29], miR-205 [30], and miR-192 [17,31]
have been shown to be associated with tumor suppressor activity in
breast cancer.
miR-192 was ﬁrst cloned by Lagos-Quintana et al. and later con-
ﬁrmed by Lim et al. [32,33]. The miR-192 gene is located on humanFig. 1. BMP-6 inhibits MDA-MB-231 cell proliferation. A. MDA-MB-231 cells were cultured wit
CCK-8 assay. * indicates p b 0.05 compared with the control (one-way ANOVA followed by T
was measured using the CCK-8 assay at the indicated time points. * indicates p b 0.05 compa
cells were cultured in the presence or absence of 150 ng/ml BMP-6. Cell proliferation assayswe
Scale bars, 25 μm. D. MDA-MB-231 cells were stably transfected with the human BMP-6 expre
was determined byWestern blotting. Actin was used to normalize the BMP-6 levels. ΔBMP-6 o
using the CCK-8 assay. * indicates p b 0.05 compared with the ΔControl (one-way ANOVA fol
proliferation was measured by immunoﬂuorescent analysis of EdU incorporation. Scale bars, 2chromosome 11 and is transcribed as a cluster with miR-194 [31,34].
In addition to breast cancer, down-regulation of miR-192 expression
has also been associatedwith liver cancer [35], kidney cancer [36], mul-
tiplemyeloma [37], and gastric cancer [38].miR-192may be involved in
cancer development through effects on cellular proliferation. In colon
cancer, miR-192 has been shown to inhibit cellular proliferation andh the indicated concentrations of BMP-6 for 6 days. Cell growth was measured using the
ukey's HSD test). B. MDA-MB-231 cells were cultured in 150 ng/ml BMP-6. Cell growth
red with the control (one-way ANOVA followed by Tukey's HSD test). C. MDA-MB-231
re performed by immunoﬂuorescent analysis of EdU incorporation at 48 h after treatment.
ssion plasmid (ΔBMP-6) or empty vector control (ΔControl). Expression of BMP-6 protein
rΔControl cells were cultured for the indicated periods of time. Cell growth wasmeasured
lowed by Tukey's HSD test). E. ΔBMP-6 or ΔControl cells were cultured for 48 h, and cell
5 μm.
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Fig. 3.miR-192 mediates BMP-6-inhibited cell proliferation. A. MDA-MB-231 cells were transiently transfected with miR-192 mimic or the control. Cell proliferation was measured by
immunoﬂuorescent analysis of EdU incorporation at 48 h after transfection. Scale bars, 25 μm. B. MDA-MB-231 cells were transiently transfected with miR-192 inhibitor or the control.
Cell proliferation was measured by immunoﬂuorescent analysis of EdU incorporation at 48 h after transfection. Scale bars, 25 μm. C. MDA-MB-231 cells were cultured with the indicated
concentrations of BMP-6 for 12 h. miR-192mRNA down-regulation was veriﬁed by Q-PCR. GAPDHwas used to normalize themiR-192 levels. * indicates p b 0.05 comparedwith the con-
trol (one-way ANOVA followed by Tukey's HSD test). D. MDA-MB-231 cells were cultured in 150 ng/ml BMP-6. miR-192 mRNA down-regulation was veriﬁed by Q-PCR at the indicated
time points. GAPDHwas used to normalize themiR-192 levels. * indicates p b 0.05 comparedwith the control (one-way ANOVA followed by Tukey's HSD test). E. MDA-MB-231 cells were
pre-incubatedwith SP600125 (10 μM), PD98059 (10 μM), SB203580 (10 μM), or PKI (5 μg/μl) for 0.5 h followed by treatment with 150 ng/ml BMP-6. miR-192mRNA expressionwas de-
termined by Q-PCR at the indicated time points following treatment. GAPDHwas used to normalize themiR-192 levels. * indicates p b 0.05 in an unpaired Student's t-test comparedwith
the control. F. MDA-MB-231 cells were transiently transfected with miR-192 inhibitor or the control followed by treatment with 150 ng/ml BMP-6. Cell growth was measured using the
CCK-8 assay at the indicated time points. * indicates p b 0.05 compared with BMP-6 alone (one-way ANOVA followed by Tukey's HSD test). G. MDA-MB-231 cells were transiently
transfected withmiR-192 inhibitor or the control followed by treatment with 150 ng/ml BMP-6 for 48 h. Cell proliferation wasmeasured by immunoﬂuorescent analysis of EdU incorpo-
ration. Scale bars, 25 μm.
2383F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–2390induce cell cycle arrest through the regulation of cyclin-dependent ki-
nase inhibitors (CKIs), such as p21 and p27, in a p53-dependentmanner
[39,40]. However, the potential role of miR-192 in cell cycle regulation
in breast cancer remains to be elucidated.
In this study, we report that elevated expression of BMP-6 inhibits
G1/S cell cycle progression in MDA-MB-231 cells, resulting in impaired
tumorigenesis in a nude mouse xenograft model. We further demon-
strate that BMP-6 inhibits cell proliferation via down-regulation of
miR-192. Importantly, analysis of miRNA expression in clinical speci-
mens showed that the expression of miR-192 is signiﬁcantly down-
regulated in breast cancer tissues and positively correlates with the
expression of BMP-6, indicating that BMP-6 and miR-192 might be
promising therapeutic targets for breast cancer treatment.2. Materials and methods
2.1. Plasmid construction
Generation of the full-length human BMP-6 expression vector has
previously been described [41]. The 3′-UTR of the wild-type RB1
gene was PCR ampliﬁed from human blood genomic DNA using the
following primers: forward, 5′-CATCTCGAGATCAAGGGTCATTATGG
GTTAG-3′and reverse, 5′-CCTGCGCGCTACAAAAAAGCAATAAAGCAA
TAAT-3′. The XhoI/Not I site-tagged potential target sequence was
then cloned into the XhoI/Not I site of psiCHECK-2 vector. RB1-3′-UTR
target site-directed mutagenesis was performed using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene) with the forward primer
5′-CTGCATGAATATCATACAAATCAGTTAGTTTTTAccTgAAGGGCTTACTATT
TCTG-3′ and the reverse primer 5′-CAGAAATAGTAAGCCCTTcAggTAAA
AACTAACTGATTTGTATGATATTCATGCAG-3′.2.2. Cell culture and transfection
MDA-MB-231 human breast cancer cells were maintained in high
glucose Dulbecco's Modiﬁed Eagle Medium (DMEM) (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen), penicillin,
and streptomycin. The cells were transfected using TurboFect™ Transfec-
tion Reagent (Fermentas) according to the manufacturer's protocols.
The human BMP-6 expression plasmid was introduced into MDA-
MB-231 cells by transient transfection. G418-resistant clones were
isolated over a period of 3–4 weeks. Overexpression of BMP-6was con-
ﬁrmed by Western blotting.
2.3. Western blotting and antibodies
Total cell extract preparation and Western blotting with the
appropriate antibodies were performed as previously described [14].
The following antibodies (Abs) were used at 1:1000 dilutions: rabbit
polyclonal Ab against BMP-6 (ab94639; Abcam), rabbit polyclonal Ab
against ID1 (18475-1-AP; Proteintech), rabbit polyclonal Ab against
CCNA1 (13295-1-AP; Proteintech), rabbit polyclonal Ab against
RB1 (#9313; Cell Signaling), and mouse monoclonal Ab against actin
(A-4700; Sigma).
2.4. Tissue samples
Fresh breast cancer tissue and corresponding non-cancer tissue from
invasive ductal carcinomas were obtained from the Tissue Banking
Facility that is jointly supported by the TMUCIH (Tianjin Medical Uni-
versity Cancer Institute and Hospital) and NFCR (National Foundation
for Cancer Research). Tissue samples were collected from a total of 30
subjects, including 15 ER/PR-positive samples and 15 ER/PR-negative
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Fig. 4.miR-192 expression is down-regulated and positively correlateswith BMP-6 expression in breast cancer specimens. A. The expression levels ofmiR-192mRNAwere determined in both
tumor tissues (T) and correspondingnormal tissues (N)byQ-PCR.GAPDHwasused to normalize themiR-192 levels. B. The averagemiR-192mRNAexpressionwashigher in the corresponding
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sion levels were determined in tumor samples from 30 breast cancer specimens by Q-PCR. GAPDH was used to normalize the individual expression levels. Expression of miR-192 positively
correlates with that of BMP-6 (r = 0.746, p = 0.015).
2384 F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–2390samples. All patients were diagnosed with histologically conﬁrmed
breast cancer and were recruited from the same department. This
study was approved by the institutional ethics committee.2.5. Tumor formation in BALB/c nude mice
All experimental procedures involving animals were performed
according to the institutional ethical guidelines for animal experiments
at the Medical College of Nankai University. MDA-MB-231 cells stably
transfected with the human BMP-6 expression plasmid (ΔBMP-6) or
empty vector (ΔControl) were collected and suspended in 50 μl of
phosphate-buffered saline (PBS) at a concentration of 2 × 107 cells/ml,
then injected into the mammary fat pads of the same female nude
mice (mean body weight: 24.7 ± 0.5 g; n = 7). The mice were
sacriﬁced when tumor masses were detected 3 weeks after surgery.
The tumor volume (V) was calculated by measuring the length (L) and
width (W) of the tumor with calipers and using the formula V =Table 1
Genes regulated by BMP-6.
Unigene GenBank™
accession no.
Symbol Description Fold change
(rhBMP-6 vs.
Control)
p value
Hs.504609 NM_002165 ID1 Inhibitor of DNA
binding 1
4.1067 0.0128
Hs.417050 NM_003914 CCNA1 Cyclin A1 −2.3376 0.0157
Hs.408528 NM_000321 RB1 Retinoblastoma 1 −2.6976 0.0358(L × W2) × 0.5. Tumor tissues were also processed and sectioned for
histological evaluation.
2.6. Immunohistochemical analysis
Immunohistochemical analysis of parafﬁn-embedded sections was
performed using the Envision Kit (Dako) following the manufacturer's
protocols. The sections were boiled in retrieval solutions to expose the
antigens. Monoclonal Abs against PCNA (60097-1-Ig; Proteintech) and
control primary antibodies were applied to the sections at a 1:800
dilution. The slides were counterstained with hematoxylin, dehydrated,
and mounted. Immunostaining was independently evaluated by 2
pathologists.
2.7. Synthesis of miRNA mimic and miRNA inhibitor
The miR-192 mimic and inhibitor were designed and synthesized
by GenePharma. The miRNA inhibitor contained all nucleotides with
2′-O-methylmodiﬁcation.
2.8. Cell viability assay
MDA-MB-231 cells were seeded onto 96-well plates at a density of
2 × 103 cells/well and incubated in DMEM containing 5% FBS at 37 °C
in the presence of multiple concentrations of BMP-6 (R&D Systems)
for 6 days. Cell viability was assessed using the CCK-8 assay according
to the manufacturer's protocols (Dojindo). Six parallel replicates were
measured for each sample.
2385F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–23902.9. 5-Ethynyl-2′-deoxyuridine (EdU) cell proliferation assay and
immunoﬂuorescent analysis
MDA-MB-231 cells transiently transfected with the miR-192 mimic
or inhibitor in the presence or absence of 150 ng/ml BMP-6 were seed-
ed onto 24-well plates at 50–60% conﬂuence. Cells were incubated with
50 μM EdU for 2 h at 48 h after transfection. After the 2-h pulse, the
cells were washed twice with PBS and ﬁxed with 4% paraformaldehyde
at room temperature for 30 min. The cells were subsequently washed
with glycine (2 mg/ml) for 5 min, added 0.2% Triton X-100 for
10 min, washed with PBS twice, and added click reaction buffer (Tris–
HCl, pH 8.5, 100 mM; CuSO4, 1 mM; Apollo 550 ﬂuorescent azide,
100 mM; ascorbic acid, 100 mM) for 30 min while protecting from
light. The cells were then washed again with 0.5% Triton X-100 for
three times, stained with Hoechst (5 mg/ml) for 30 min at room
temperature, washed with 0.5% Triton X-100 for three times. Images
were taken and analyzed using Confocal FV1000 (Olympus). EdU
positive cell was calculated with (EdU add-in cells / Hoechst stained
cells) × 100%. At least 200 cells were counted per well.0
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Fig. 5. BMP-6 inhibits cell proliferation by altering the levels of cell cycle regulators. MDA-MB-2
(A), CCNA1 (B), and RB1 (C) was examined by Q-PCR andWestern blotting. GAPDH and actinw
Student's t-test compared with the control.2.10. RNA extraction and quantitative RT-PCR
Using TRIzol Reagent (Invitrogen), total RNA was extracted from
MDA-MB-231 cells that were either treated withmultiple concentrations
of BMP-6 or transfected with the miR-192 mimic/inhibitor. Total RNA
(0.5 μg) from each sample was used for ﬁrst-strand cDNA synthesis
using M-MLV Reverse Transcriptase (Promega). The speciﬁc products of
human miR-192 and RB1 were ampliﬁed by quantitative PCR (Q-PCR)
using the following primers: miR-192, 5′-GCTGTTATCTGGGGCGAGGG-
3′ (forward) and 5′-GGTGGGACCATGAGTGCTGC-3′ (reverse); and RB1,
5′-TCGCTTGTATTACCGAGTA-3′ (forward) and 5′-ATCAGTTGGTCCTTC
TCG-3′ (reverse). Veriﬁcation of gene expression levels was performed
by quantitative RT-PCR using EvaGreen (Biotium). GAPDH was used as
an internal control.
2.11. Luciferase assay
MDA-MB-231 cellswere co-transfectedwith thewild-type ormutant
RB1-3′-UTR plasmid and miR-192 mimic/inhibitor in the presence oranti-ID1
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2386 F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–2390absence of 150 ng/ml BMP-6 in 24-well plates. Lysates were prepared,
and luciferase activities were measured using the Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer's pro-
tocols. The luciferase activities were normalized to the values for Renilla
luciferase.0
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Total RNA was extracted from MDA-MB-231 cells cultured in the
presence or absence of 150 ng/ml BMP-6 for 24 h. For PCR array exper-
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2387F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–2390examine the mRNA levels of 84 genes closely associated with breast
cancer, including 5 “housekeeping genes”, in 96-well plates following
the manufacturer's protocol (APH-028X, QIAGEN). Brieﬂy, ﬁrst-strand
cDNAs were synthesized from 1 μg of total RNA using the TaqMan RT
reagent kit (QIAGEN) according to the manufacturer's protocol. The re-
actionmixtures (25 μl) were incubated at 25 °C for 10 min, followed by
incubation at 48 °C for 30 min and 95 °C for 5 min, then cooled on ice.
Arrays were performed independently at least three times for each cell
line; valueswere obtained for the threshold cycle (Ct) for each gene and
normalized using the average of ﬁve housekeeping genes on the same
array (HPRT1, RPLP0, GAPDH, B2M, and ACTB). The Ct values for house-
keeping genes and a dilution series of ACTB were monitored for
consistency between the arrays. The change (ΔCt) between BMP-6
and Control was determined using the formula ΔCt = Ct(BMP-6) −
Ct(Control), and the fold change was determined using the formula
fold change = 2(−ΔCt). The resulting values were reported as fold
change; only genes showing twofold or greater change were consid-
ered. The negative controls ensured the absence of DNA contamination
and set the threshold for determining the absence versus presence of
expression.
2.13. Statistical analysis. SPSS 17.0 software (SPSS) was used for statisti-
cal analysis. The data from all the experiments are presented as
means ± SD and represent three independent experiments. One-way
analysis of variance (ANOVA) was used to compare means between
treatment groups and Tukey's HSD (honestly signiﬁcant difference)
test was used to evaluate the statistically signiﬁcant differences be-
tween groups. Where appropriate, Student's t-test for unpaired obser-
vations was applied. A p-value b 0.05 was considered signiﬁcant.
3. Results
3.1. BMP-6 inhibits MDA-MB-231 cell proliferation
To assess the possible role of BMP-6 in breast cancer cell prolifera-
tion, MDA-MB-231 cells were treated with 0, 50, 100, and 150 ng/ml
BMP-6 for 6 days. As shown in Fig. 1A, the cell viability assay indicated
that BMP-6 inhibits cell growth in a dose-dependent manner. Treat-
ment with 150 ng/ml BMP-6 for the indicated periods of time caused
a signiﬁcant decrease in cell number compared with control cells,
conﬁrming that BMP-6 inhibits proliferation in MDA-MB-231 cells
(Fig. 1B). Immunoﬂuorescence of EdU cell proliferation assay revealed
a marked decrease in the number of cells in S phase after treatment
with BMP-6 (Fig. 1C). The percentage of cells in S phase decreased
from 74.06% to 45.91% at 48 h after addition of BMP-6.
MDA-MB-231 cells were stably transfected with either the full-
length BMP-6 expression plasmid (ΔBMP-6) or the empty vector
(ΔControl). Overexpression of BMP-6 was assessed byWestern blotting
(Fig. 1D). The cell viability assay indicated that ectopic expression of
BMP-6 in MDA-MB-231 cells inhibits proliferation compared with
ΔControl cells (Fig. 1D). The Edu assay indicated that the percentage
of cells in S phase decreased from 73.79% in ΔControl cells to 49.60%
in ΔBMP-6 cells at 48 h (Fig. 1E). Taken together, these data suggestFig. 6. BMP-6/miR-192 targets RB1. A. ThemiR-192 binding site in the predicted target sequence
RB1-3′UTR orM-RB1-3′UTR (1 μg/well) andmiR-192mimic ormiR-192 inhibitor (50 nM). The
analyzer. Luciferase values were normalized using Renilla activities. * indicates p b 0.05 in an u
transfected with miR-192 mimic. RB1 mRNA and protein expression was determined by Q-PC
used to normalize the RB1 levels. * indicates p b 0.05 compared with the control (one-way A
withmiR-192 inhibitor. RB1mRNA and protein expressionwas determined by Q-PCR andWest
malize the RB1 levels. * indicates p b 0.05 compared with the control (one-way ANOVA followe
M-RB1-3′UTR (1 μg/well) and miR-192 inhibitor (50 nM), followed by treatment with 150 ng
using a Betascope analyzer. The luciferase values were normalized using Renilla activities. * in
231 cells were cultured in the presence of 150 ng/ml BMP-6. RB1mRNA and protein expression
GAPDH and actinwere used to normalize the RB1 levels. * indicates p b 0.05 comparedwith the
siently transfectedwithmiR-192 inhibitor followed by treatmentwith 150 ng/ml BMP-6. RB1m
at the indicated time points. GAPDH and actin were used to normalize the RB1 levels.that BMP-6 inhibits cell cycle progression through S phase in MDA-
MB-231 cells.
3.2. BMP-6 inhibits tumorigenesis in vivo
To conﬁrm the potential role of BMP-6 in cell growth in vivo, we
established a BALB/c nude mouse xenograft model using the ΔBMP-6
stable cell line. ΔBMP-6 or ΔControl cells were injected into mammary
fat pads of the same nude mouse. MDA-MB-231 cells stably
overexpressing BMP-6 formed smaller tumors and grew more slowly
than the control transfected cells (Fig. 2A). The tumor volumes and
weights in the mice injected with ΔBMP-6 cells were signiﬁcantly
lower than in those injected with ΔControl cells (Fig. 2B and C). West-
ern blottingwas used to conﬁrm the up-regulation of BMP-6 expression
in tumors from ΔBMP-6 mice (Fig. 2D). Interestingly, as shown in
Fig. 2E, the expression of proliferating cell nuclear antigen (PCNA)
was signiﬁcantly down-regulated in tumors from ΔBMP-6 mice com-
pared to those from ΔControl mice. These results indicate that BMP-6
inhibits the tumorigenesis of MDA-MB-231 cells in vivo in a nude
mouse xenograft model.
3.3. miR-192 is up-regulated by BMP-6 and affects MDA-MB-231
proliferation
We have previously reported that BMP-6/miR-192 signaling func-
tions in δEF1-regulated breast cancer invasion [17]. Here, we extended
our study to elucidate the relationship between BMP-6 and miR-192
in breast cancer proliferation. MDA-MB-231 cells were transiently
transfectedwithmiR-192mimic ormiR-192 inhibitor. The Edu assay re-
vealed that the percentage of cells in S phase decreased from 72.29% to
52.28% at 48 h after miR-192 overexpression (Fig. 3A). In contrast,
transfection with miR-192 inhibitor resulted in a signiﬁcant increase
in the cell number in S phase from 73.72% to 87.36% at 48 h (Fig. 3B).
These observations indicate that miR-192 exerts a similar effect to
BMP-6 in blocking the cell cycle progression into S phase in MDA-MB-
231 cells.
Consequently, we further explored the relationship between BMP-6
and miR-192 in the regulation of cell proliferation. MDA-MB-231 cells
were cultured in 0, 50, 100, or 150 ng/ml BMP-6. Total RNA was
extracted after treatmentwith BMP-6 for 12 h. Q-PCR analysis indicated
that BMP-6 causes up-regulation of miR-192 expression in a dose-
dependent manner. Treatment with 150 ng/ml BMP-6 resulted in up
to a 12-fold increase in the expression of miR-192 mRNA compared
with the basal level (Fig. 3C). Furthermore, MDA-MB-231 cells were in-
cubated in the presence or absence of 150 ng/ml BMP-6, and miR-192
mRNA expression was examined at 0, 3, 6, 12, and 24 h after treatment.
BMP-6 induced an approximately 4-fold increase in miR-192mRNA ex-
pression compared with the basal level as early as 3 h after treatment.
At 6–12 h, BMP-6 induced a 6.5–13-fold increase in miR-192 mRNA
expression. At 24 h, BMP-6 induced a greater than 38-fold increase in
miR-192 expression over the basal level (Fig. 3D). Given that BMP-6
has been reported to potentially function through the MAPK [18,19]
and PKA [42] pathways in breast cancer, we proceeded to identify thes of the 3′-UTR of RB1 gene is indicated. MDA-MB-231 cells were co-transfectedwithWT-
luciferase activity of the extracts was determined 24 h after transfection using a Betascope
npaired Student's t-test compared with the control. B. MDA-MB-231 cells were transiently
R and Western blotting, respectively, at the indicated time points. GAPDH and actin were
NOVA followed by Tukey's HSD test). C. MDA-MB-231 cells were transiently transfected
ern blotting, respectively, at the indicated time points. GAPDH and actin were used to nor-
d by Tukey's HSD test). D. MDA-MB-231 cells were co-transfected withWT-RB1-3′UTR or
/ml BMP-6. The luciferase activity of the extracts was determined 24 h after transfection
dicates p b 0.05 in an unpaired Student's t-test compared with the control. E. MDA-MB-
was determined by Q-PCR andWestern blotting, respectively, at the indicated time points.
control (one-way ANOVA followed by Tukey's HSD test). F. MDA-MB-231 cells were tran-
RNA and protein expressionwas determined byQ-PCR andWestern blotting, respectively,
2388 F. Hu et al. / Biochimica et Biophysica Acta 1832 (2013) 2379–2390downstream signaling mechanism(s) for BMP-6-induced miR-192 ex-
pression. MDA-MB-231 cells were treated with the following inhibitors
in the presence of 150 ng/ml BMP-6: SP600125 (JNK inhibitor),
PD98059 (ERK inhibitor), SB203580 (p38 inhibitor), and PKI (PKA in-
hibitor). As shown in Fig. 3E, Q-PCR indicated that treatment with
SB203580 signiﬁcantly blocks BMP-6-induced miR-192 expression at
the mRNA level compared with the control. However, inhibition of
JNK, ERK and PKA signaling by SP600125, PD98059 and PKI, respective-
ly, did not interferewithmiR-192mRNAup-regulation by BMP-6. These
observations suggest that the p38 pathway speciﬁcally contribute to
BMP-6-regulated miR-192 expression in MDA-MB-231 cells.
To further investigate whether BMP-6-mediated inhibition of cell
proliferation occurs via miR-192, MDA-MB-213 cells were transfected
with miR-192 inhibitor followed by treatment with 150 ng/ml BMP-6.
The cell viability assay indicated that BMP-6-mediated inhibition of
cell proliferation is signiﬁcantly abolished by depletion of miR-192
(Fig. 3F). In addition, the EdU assay conﬁrmed that BMP-6 induction re-
sults in a decrease in the percentage of cells in S phase from 73.97% to
48.64% at 48 h (Fig. 3G). However, upon addition of miR-192 inhibitor,
the percentage of cells in S phasewas approximately 70.61%, suggesting
that the cell cycle inhibition caused by BMP-6 is mediated by miR-192.
Taken together, these results imply that miR-192 expression is up-
regulated by BMP-6 in MDA-MB-231 cells. This ﬁnding at least partially
contributes to understanding the mechanism by which BMP-6 blocks
the G1/S transition in the cell cycle.
3.4. miR-192 expression is down-regulated in human breast cancer
Loss ofmiR-192 expression has been reported in colon and lung can-
cers [40,43]. Here, we compared the endogenous expression ofmiR-192
in human breast cancer and adjacent non-cancerous breast tissues byQ-
PCR. As shown in Fig. 4A, down-regulation of miR-192 expression was
observed in 83.3% (25 out of 30) of breast cancer tissues compared
with the corresponding adjacent non-cancerous breast tissues. More-
over, the average miR-192 mRNA expression in breast cancer tissues
was signiﬁcantly lower than that in the corresponding adjacent non-
cancerous tissues (Fig. 4B). Importantly, we explored the relationship
between BMP-6 and miR-192 expression in breast cancer tissues. As
shown in Fig. 4C, miR-192 expression positively correlated with BMP-
6 expression (r = 0.746, p = 0.015). These observations indicate that
miR-192 may act as a tumor suppressor gene in the development of
breast cancer.
3.5. BMP-6/miR-192 signaling targets RB1
To further identify the potential cellular pathways regulated by
BMP-6, differences in the mRNA levels of selected signaling molecules
were examined using the RT2 Proﬁler PCR Array by comparing BMP-
6-treated MDA-MB-231 cells with control cells. Alterations in the ex-
pression of several cell cycle regulators, including ID1, CCNA1, and
RB1, were observed (Table 1). Q-PCR and Western blotting were
performed to verify these ﬁndings (Fig. 5A–C).
Interestingly, using the open access programs miRnaDa and PicTar,
the RB1 gene was predicted to be targeted by miR-192 (the predicted
binding sites for miR-192 are shown in Fig. 6A). Thus, the 3′-UTR of the
RB1 gene was cloned into the psiCheck-2 vector. The luciferase reporter
activity of WT-RB1-3′UTR decreased upon transfection with miR-192
mimic; in contrast, miR-192 inhibitor treatment caused an increase in
reporter activity (Fig. 6A). Furthermore, site-directed mutagenesis of
the reporter containing the 3′-UTR of the RB1 gene was performed
(Fig. 6A), and the luciferase reporter activity of the mutated construct
was assessed. The regulatory effect of either miR-192 mimic or miR-192
inhibitor was abolished in the mutant M-RB1-3′UTR reporter (Fig. 6A).
Q-PCR and Western blotting analysis revealed that the expression of
RB1 mRNA and protein was affected by treatment with either miR-192
mimic ormiR-192 inhibitor inMDA-MB-231 cells (Fig. 6B andC). Notably,knockdownof RB1 expressionusing a siRNA targeting RB1 (siRB) resulted
in an inhibition of the cell cycle progression into S phase (Fig. S1),which is
similar to the effect of miR-192 overexpression. On the contrary, the res-
cue of RB1 expression inmiR-192 overexpressing cells signiﬁcantly atten-
uated miR-192-induced cell cycle arrest (Fig. S2), showing that the cell
cycle inhibition caused by miR-192 is mediated by RB1.
Furthermore, BMP-6 induction impaired the reporter activity of
WT-RB1-3′UTR (Fig. 6D); this ﬁnding is consistent with the effect
of transfection with miR-192 mimic. However, transfection with miR-
192 inhibitor alleviated the BMP-6-mediated repression of WT-RB1-3′
UTR reporter activity. Mutation of the reporter containing the 3′-UTR
of the RB1 genewas sufﬁcient to interferewith the BMP-6-regulated re-
porter activity of M-RB1-3′UTR in a miR-192-independent manner.
Moreover, Q-PCR and Western blotting analysis revealed that RB1
mRNA and protein expression was down-regulated by addition of
BMP-6, and this effect on RB1 expression was attenuated by transfec-
tion with miR-192 inhibitor (Fig. 6E and F). Collectively, these observa-
tions indicate that RB1 is a major target in BMP-6/miR-192-regulated
MDA-MB-231 cell proliferation.
4. Discussion
Breast cancer results from cell cycle disorganization that leads to un-
controlled cellular proliferation. Speciﬁc cellular processes that control
cell cycle progression and checkpoints through the intermitotic phases
are deregulated. Several studies have reported that breast cancer pro-
duces various growth factors that contribute to tumor progression and
proliferation. In the present study, we identiﬁed the contribution of
one of these factors, BMP-6, to the regulation of MDA-MB-231 cell pro-
liferation. Elevated BMP-6 expression resulted in the repression of G1/S
phase cell cycle progression and inhibited the tumorigenesis of MDA-
MB-231 cells in a nudemouse xenograftmodel.We further demonstrat-
ed that BMP-6 inhibits cell proliferation via down-regulation of
miR-192. The cell cycle regulator, RB1 is a major target of BMP-6/
miR-192 signaling in the regulation of MDA-MB-231 cell proliferation.
Although BMPs are well known to be morphogens in embryonic de-
velopment, organogenesis, and adult tissue homeostasis [6,44], the role
of BMPs as tumor suppressors in tumor progression is largely unsettled.
The BMP antagonist Noggin promotes skin tumorigenesis via stimula-
tion of the Wnt and Shh signaling pathways, suggesting that BMPs act
as tumor suppressors in the skin epithelium [45]. Moreover, BMP-2
and -4 have been shown to play tumor suppressor roles in human
gastric carcinoma [46,47]. We have recently reported that BMP-6 in-
hibits EMT in breast cancer, and decreased BMP-6 expression correlates
with poor prognosis and disease progression, particularly lymphatic
metastasis [14,16]. In the present study, we further demonstrated that
BMP-6 signiﬁcantly inhibits cell proliferation inMDA-MB-231 cells. Ele-
vated expression of BMP-6 results in decreased tumorigenesis in vivo in
a nude mouse xenograft model. Importantly, the EdU cell proliferation
assay showed that induction of BMP-6 prevents cells from completing
the G1/S transition, thus delaying cell cycle progression. This result is
consistent with a previous report indicating that BMP-6 and -7 inhibit
estrogen-induced proliferation of MCF-7 breast cancer cells; this pro-
cess is mediated by suppression of p38 activation [19].
Moreover, our observations showed that miR-192 may function
downstream of BMP-6 in the regulation of MDA-MB-231 proliferation.
Expression of miR-192 mRNA is signiﬁcantly induced by BMP-6 and
causes G1/S arrest, similar to the effect of BMP-6. Depletion of miR-192
expression using amiRNA inhibitor abolishes BMP-6-mediated inhibition
of MDA-MB-231 proliferation, positioning miR-192 as a critical down-
streammediator of BMP-6 signaling in cell cycle regulation. These results
are consistent with those observed in human colon cancer cells, in which
miR-192 functions as both an effector and regulator of p53 and sup-
presses carcinogenesis through p21 accumulation and cell cycle arrest
[39,40]. Additionally, our results demonstrated that miR-192 is down-
regulated in breast cancer tissues compared with adjacent non-tumor
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cer [39], lung cancer [43], ulcerative colitis [48], and multiple myeloma
[37]. These results suggest that miR-192 is a tumor suppressor and may
be useful as a future drug target for controlling cancer progression.
RB1 proteins play key roles in regulating cell cycle arrest and drive
tumorigenesis by overcoming barriers to cellular proliferation [49-51].
Consequently, factors that modulate RB1 function are of great clinical
importance. Here, we show that miR-192 is differentially expressed in
human breast cancer and tightly regulates the expression of RB1 by spe-
ciﬁcally targeting a conserved sequence motif in the 3′-UTR of RB1.
Thus, miR-192 inhibits RB1 expression at both the mRNA and protein
levels. Although loss of RB1 is expected to be associated with increased
cell proliferation, we found that MDA-MB-231 cells display signiﬁcantly
reduced cell proliferation rates when transiently transfected with miR-
192. Cell cycle proﬁles revealed that EdU incorporation into the DNA of
replicating cells was also signiﬁcantly reduced in these cells. These re-
sults are consistent with those of previous reports suggesting that
down-regulation of RB1 inhibits cell proliferation and induces apoptosis
in human lung and osteosarcoma cancers [43,51]. Our data also suggest
that by altering the miR-192 levels, BMP-6 may function in the RB1
tumor regulator pathway to limit cell proliferation in breast cancer. In
addition to RB1, obvious candidates for involvement in BMP-6-
regulated breast cancer cell proliferation, such as ID1 and CCNA1,
were identiﬁed in the present study. However, these genes are not po-
tential targets of miR-192 (unpublished data). These results indicate
that a miR-192-independent mechanism might contribute to BMP-6-
mediated cell cycle arrest in breast cancer.
In summary, we have provided a novel potential mechanism for
BMP-6/miR-192-mediated cell growth arrest in breast cancer through
down-regulation of RB1. Therefore, we suggest that BMP-6 or pathways
downstream of BMP-6, such as miR-192, may be viable therapeutic tar-
gets. Activation of BMP-6 and/or miR-192 expression may represent a
new therapeutic strategy for controlling breast cancer.
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